H-SLL^MWITQC-OH

Rif. 3D-PP47308

Informazioni sul prodotto

• Nome: H-SLL^MWITQC-OH

Descrizione

Peptide H-SLL^MWITQC-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-SLL^MWITQC-OH include the following: Predicting peptide binding affinities to MHC molecules using a modified semi-empirical scoring function WWP Liao, JW Arthur - PLoS One, 2011 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0025055 Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination Q Chen , H Jackson, M Shackleton , P Parente - Cancer Immunity, 2005 - AACRhttps://aacrjournals.org/cancerimmun/article-abstract/5/1/5/471995 Quantifying and Imaging P Vyas, JL Chen , V Cerundolo, BK Karbach, E Jager - J Immunol, 2006 - academia.eduhttps://www.academia.edu/download/68505824/7308.full.pdf CD8+ T-Cell Response to NY-ESO-1: Relative Antigenicity and in Vitro Immunogenicity of Natural and Analogue Sequences P Romero, V Dutoit , V Rubio-Godoy, D Liénard - Clinical cancer , 2001 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/7/3/766s/200053 Application of the DARPin® technology for specific targeting of tumor-associated MHC class I:peptide complexes N Venetz, S Muller, T Schulte , S Fischer, M Paladino - Cancer Research, 2021 - AACRhttps://aacrjournals.org/cancerres/article-abstract/81/13_Supplement/1349/667274 Juan Campos-Perez1, Jason Rice1, David Escors2, 3, Mary Collins2, Alex Paterson1, Natalia Savelyeva1* and Freda K Stevenson1*. 1Genetic Vaccine Group N Savelyeva - academia.eduhttps://www.academia.edu/download/32110545/Campos_Perez_et_al_2013.pdf Human leucocyte antigen class I-redirected anti-tumour CD4+ T cells require a higher T cell receptor binding affinity for optimal activity than CD8+ T cells MP Tan, GM Dolton , AB Gerry, JE Brewer - Clinical & , 2017 - academic.oup.comhttps://academic.oup.com/cei/article-abstract/187/1/124/6412049 Application of the DARPin® technology for specific targeting of tumor-associated MHC class I:peptide complexes M Walcer, N Venetz, T Schulte , S Fischer, N Bassler - Cancer Research, 2020 - AACRhttps://aacrjournals.org/cancerres/article/80/16_Supplement/690/644831 Crystal structures of high affinity human T-cell receptors bound to peptide major histocompatibility complex reveal native diagonal binding geometry M Sami, PJ Rizkallah , S Dunn, P Molloy - , Design & Selection, 2007 - academic.oup.comhttps://academic.oup.com/peds/article-abstract/20/8/397/1434666 Non-covalent glycosylated gold nanoparticles/peptides nanovaccine as potential cancer vaccines L Zeng, Z Liao, W Li, Q Yuan , P Wu, Z Gu , Z Liu - Chinese Chemical , 2020 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1001841719306199 Real time detection of peptide-MHC dissociation reveals that improvement of primary MHC-binding residues can have a minimal, or no, effect on stability KM Miles, JJ Miles , F Madura, AK Sewell , DK Cole - Molecular immunology, 2011 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0161589010006073 Structural and kinetic basis for heightened immunogenicity of T cell vaccines JL Chen , G Stewart-Jones, G Bossi, NM Lissin - The Journal of , 2005 - rupress.orghttps://rupress.org/jem/article-abstract/201/8/1243/52591 On Conformations of Peptides Bound to Class I Major Histocompatibility Complexes J Wang, BY Chen - Proceedings of the 10th ACM International , 2019 - dl.acm.orghttps://dl.acm.org/doi/abs/10.1145/3307339.3343868 DNA fusion vaccine designs to induce tumor-lytic CD8+ T-cell attack via the immunodominant cysteine-containing epitope of NY-ESO 1 J Campos-Perez, J Rice, D Escors - journal of cancer, 2013 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.28156 Lipopeptides for vaccine development IW Hamley - Bioconjugate Chemistry, 2021 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/acs.bioconjchem.1c00258 Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans ID Davis , W Chen , H Jackson - Proceedings of the , 2004 - National Acad Scienceshttps://www.pnas.org/doi/abs/10.1073/pnas.0403572101 and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1157-165 tumor-specific peptide E Shenderov , M Kandasamy, U Gileadi - for immunotherapy of , 2021 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183295/ T cell receptor engagement of peptide-major histocompatibility complex class I does not modify CD8 binding DK Cole , SM Dunn, M Sami, JM Boulter - Molecular , 2008 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0161589007008954 Naturally Occurring Human Lymphocyte Antigen-A2 Restricted CD8+ T-Cell Response to the Cancer Testis Antigen NY-ESO-1 in Melanoma Patients D Valmori, V Dutoit , D Liénard, D Rimoldi, MJ Pittet - Cancer research, 2000 - AACRhttps://aacrjournals.org/cancerres/article-abstract/60/16/4499/506558 Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA CJ Holland, RM Crean , JM Pentier - The Journal of , 2020 - Am Soc Clin Investighttps://www.jci.org/articles/view/130562 TCR fingerprinting and off-target peptide identification AR Karapetyan, C Chaipan, K Winkelbach - Frontiers in , 2019 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fimmu.2019.02501/full Impact of cysteine residues on MHC binding predictions and recognition by tumor-reactive T cells A Sachs , E Moore, Z Kosaloglu-Yalcin - The Journal of , 2020 - journals.aai.orghttps://journals.aai.org/jimmunol/article/205/2/539/110175

• Marchio: Biosynth